• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND DIAGNOSTICS DIVISION ARCHITECT HBSAG QUALITATIVE; TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND DIAGNOSTICS DIVISION ARCHITECT HBSAG QUALITATIVE; TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM) Back to Search Results
Catalog Number 04P53-25
Medical Device Problem Code False Positive Result (1227)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 12/18/2025
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.All available patient information was included.Additional patient details are not available.
 
Event or Problem Description
The customer observed false repeat reactive architect hbsag qualitative results which questioned by the physician for several patients.The one result example provided were: initial=1.23 s/co (> or =1.00 s/co=reactive) /repeated after redrawn multiple times same patient=1.6, 1.7 and 1.33 s/co hbsag qual confirmatory c2=1.55 s/co; % neutralization=99% (c2=> or =0.70 s/co and % neutralization=> or =50%=confirmed positive) additional information provided: all other hepatitis b markers are negative (no actual results provided) there was no reported impact to patient management.
 
Additional Manufacturer Narrative
The complaint evaluation included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, device history record review for architect hbsag qualitative reagent, lot 78397fz00.Data and information provided by the customer were reviewed and support the complaint issue without indication for any additional issue.Review of tracking and trending for the architect hbsag qualitative assay did not identify an increase in complaint activity related to the complaint issue.Additionally, an increase in complaint activity was not identified for reagent lot 78397fz00.Device history record review did not identify any non-conformances or deviations with the complaint lots and complaint issue.A review of the product labeling concluded that the issue is sufficiently addressed.There was no issue with reagent performance identified.Based on the investigation, the device met performance specification and performed as intended at the customer site, therefore there is no systemic issue or deficiency with the architect hbsag qualitative reagent, lot 78397fz00.
 
Event or Problem Description
The customer observed false repeat reactive architect hbsag qualitative results which questioned by the physician for several patients.The one result example provided were: initial=1.23 s/co (> or =1.00 s/co=reactive) /repeated after redrawn multiple times same patient=1.6, 1.7 and 1.33 s/co.Hbsag qual confirmatory c2=1.55 s/co; % neutralization=99% (c2=> or =0.70 s/co and % neutralization=> or =50%=confirmed positive).Additional information provided: all other hepatitis b markers are negative (no actual results provided).There was no reported impact to patient management.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT HBSAG QUALITATIVE
Common Device Name
TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
Manufacturer (Section D)
ABBOTT IRELAND DIAGNOSTICS DIVISION
finisklin business park
sligo F91VY 44
EI  F91VY44
Manufacturer (Section G)
ABBOTT IRELAND DIAGNOSTICS DIVISION
finisklin business park
sligo F91VY 44
EI   F91VY44
Manufacturer Contact
nicole jenne
max-planck-ring 2
post market surveillance
wiesbaden 65205
GM   65205
6122582960
MDR Report Key23945555
Report Number3008344661-2026-00001
Device Sequence Number16114346
Product Code LOM
UDI-Device Identifier00380740007775
UDI-Public(01)00380740007775(17)260316(10)78397FZ00
Combination Product (Y/N)N
Initial Reporter StateTN
Initial Reporter CountryUS
PMA/510(K) Number
P110029
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 03/02/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date03/16/2026
Device Catalogue Number04P53-25
Device Lot Number78397FZ00
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 12/18/2025
Supplement Date Received by Manufacturer02/25/2026
Initial Report FDA Received Date01/02/2026
Supplement Report FDA Received Date03/02/2026
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured08/14/2025
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Unknown
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
ARC I2000SR INST, 03M74-02, (B)(6).; ARC I2000SR INST, 03M74-02, (B)(6).
Patient SexUnknown
-
-